Journal article

Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

Pedro Aguiar, Luke A Perry, Gilberto L Lopes

LUNG CANCER MANAGEMENT | FUTURE MEDICINE LTD | Published : 2016

DOI: 10.2217/lmt-2016-0016

University of Melbourne Researchers

Citation metrics

4Web of Science
5Dimensions

Keywords

Cell Lung-Cancer
Cost-Effectiveness
Nivolumab
Outcomes
Science & Technology
Respiratory System
Cost–effectiveness
Immunotherapy
Metaanalysis
Life Sciences & Biomedicine
Predictive Biomarker
Docetaxel
Lung Cancer
Health Technology Assessment